Highlights include Medicaid specialty drug reimbursement, managing ICD-10 implementation
The U.S. Department of Health and Human Services Office of Inspector General (OIG) issues an annual work plan summarizing the health program reviews planned by OIG for the upcoming year. Its Fiscal Year 2016 Work Plan provides important information and guidance to healthcare executives. Here are some of the key takeaways.
The work plan states that OIG expects recoveries from providers and health plans of more than $3 billion for 2015. Further, the legislative, regulatory and administrative actions OIG supported saved approximately $20.6 billion last year.
OIG reviews resulted in the exclusion of 4,112 individuals and entities from participation in federal healthcare programs; 925 criminal actions; and 682 civil actions, including false claims and unjust-enrichment cases.
In June 2015, OIG participated in the largest national healthcare fraud intervention in its history, resulting in more than 240 subjects being charged with defrauding Medicare and Medicaid.
OIG will expand its focus on delivery system reform and the effectiveness of alternate payment models, coordinated care programs and value-based care purchasing.
Data analytics will be used to identify additional issues for further analysis and scrutiny.
As more attention is directed to addressing the rising cost of healthcare, reviews and enforcement actions can be expected to increase.
Next: New areas the OIG will review
Medicaid
Medicare Parts C and D
Affordable Care Act (ACA)
Medicare Parts A and B:
Deborah Dorman-Rodriguez is a Partner at Freeborn & Peters LLP, and is the leader of the Firm's Healthcare Practice Group.
David Kaufman is a Partner at Freeborn & Peters LLP, and serves as a key member of the Firm's Healthcare Practice Group.
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen